This information is disclosed in accordance with the Securites Markets Act and NASDAQ OMX Stockholm's rules regarding public offers on the stock market.
This press release may not be distributed, directly or indirectly, in or into, Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United States of America. The Offer is not being made to (and acceptances will not be accepted from) persons in those countries or in any other country where the making of the Offer, the distribution of this press release or acceptance of the Offer requires further offer documents, filings or other measures in addition to those required by Swedish law.
Ratos owns a total of 25 936 144 shares and convertibles, corresponding to 97.57% of all shares and votes in Biolin Scientific following the end of the extended acceptance period. Settlement in respect of those that accepted the offer during the extended acceptance period is expected to commence on 3 March 2011.
Based on the final review of acceptances received during the extended acceptance period, which ended on 24 February 2011, an additional 555 623 shares and convertibles, corresponding to 2.09% of all shares and votes in Biolin Scientific, have been tendered in the offer. This means that the offer has been accepted by owners of a total of 25 198 458 shares and convertibles, corresponding to 94.80% of the capital and votes in Biolin Scientific. Together withshares acquired outside the offer on NASDAQ OMX at a price of SEK 11.50 per share, Ratos now owns 97.57% of all capital and votes (after full dilution).
For those who have accepted the offer during the extended acceptance period, settlement is expected to commence on 3 March 2011.
The acceptance period will not be extended further. Ratos has initiated compulsory acquisition of the remaining shares.
For further information, please contact:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20